2020 Revenues ($USD) : $2,903,074,000
2020 R&D spend : $158,902,000
2020 Number of Employees : 3,397
Fiscal Year End : 12/31/2020
Key People : Blaise Coleman, CEO

Endo International roots go back to a 1997 management buyout at DuPont Merck, where the generics division had gone by the name Endo Laboratories. A maker of painkillers, including Percocet, it eliminated its entire U.S. pain products sales force in December 2016 as it faced increased scrutiny amid the opioid epidemic, according to its annual report for 2020. Endo International's areas of focus in 2021 include the launch of QWO, FDA-approved for the treatment of moderate to severe cellulite in women's buttocks. The company in September 2020 inked a non-exclusive agreement to provide fill-finish manufacturing services for Novavax's COVID-19 vaccine candidate. –CN